The Cell Biology group will innovate and develop assays to validate in-cell efficacy of established and new probe families which include bromodomains, Nudix hydrolases, deaminase and DENN domains.  Each assay will be developed to address the unique biology of the target using molecular biology (inc CRISPR, RNAseq, ChIP, Mass Spectrocopy) and confocal microscopy (HTS/HCS). Further detailed investigations into the biological mechanism and disease target will be carried out both in-house and with academic and pharmaceutical industry collaborations.  By advancing SGC probes into cellular assays we aim to produce pre-clinical in vitro data to enable the translation of SGC probes into a disease area within the clinic. 

Gillian’s research interests include disease heterogeneity, multicellular and 3D disease models.